Aptevo Therapeutics Inc.

APVO ·Healthcare, Drug Manufacturers - General, United States
Financial Statements Cash Flow Statement
Annual Quarterly

Cash Flow Statement

Line Item FY2017 FY2016 FY2015
Operating Activities
Net Income $7.0M $-112.4M $-59.3M
Depreciation & Amortization $3.1M $3.4M $2.9M
Depreciation $1.5M $1.1M
Amortization $800.0K $800.0K $3.4M
Stock-Based Compensation $4.9M $3.8M $1.1M
Net Cash from Operating Activities $-41.6M $-36.9M $-48.8M
Investing Activities
Capital Expenditures $1.4M $2.5M $1.5M
Business Acquisitions
Net Cash from Investing Activities $29.5M
Financing Activities
Dividends Paid
Stock Repurchases
Net Cash from Financing Activities $19.5M
Net Change in Cash $-2.6M $5.0M $1.0M
Free Cash Flow $-43.0M $-39.4M $-50.3M
← Newer Page 2 of 2 Older →